Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes

V. Sciannameo1, P. Berchialla2, A. Avogaro3 and G. P. Fadini3*

Abstract

Background: Transferring results obtained in cardiovascular outcome trials (CVOTs) to the real-world setting is challenging. We herein transposed CVOT results to the population of patients with type 2 diabetes (T2D) seen in routine clinical practice and who may receive the medications tested in CVOTs.

Methods: We implemented the post-stratification approach based on aggregate data of CVOTs and individual data of a target population of diabetic outpatients. We used stratum-specific estimates available from CVOTs to calculate expected effect size for the target population by weighting the average of the stratum-specific treatment effects according to proportions of a given characteristic in the target population. Data are presented as hazard ratio (HR) and 95% confidence intervals.

Results: Compared to the target population (n = 139,708), the CVOT population (n = 95,816) was younger and had a two to threefold greater prevalence of cardiovascular disease. EMPA-REG was the CVOT with the largest variety of details on stratum-specific effects, followed by TECOS, whereas DECLARE and PIONEER-6 had more limited stratum-specific information. The post-stratification HR estimate for 3 point major adverse cardiovascular event (MACE) based on EMPA-REG was 0.88 (0.74–1.03) in the target population, compared to 0.86 (0.74–0.99) in the trial. The HR estimate based on LEADER was 0.88 (0.77–0.99) in the target population compared to 0.87 (0.78–0.97) in the trial. Consistent results were obtained for SUSTAIN-6, EXSCEL, PIONEER-6 and DECLARE. The effect of DPP-4 inhibitors observed in CVOTs remained neutral in the target population.

Conclusions: Based on CVOT stratum-specific effects, cardiovascular protective actions of glucose lowering medications tested in CVOTs are transferrable to a much different real-world population of patients with T2D.

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
disease [4]. More recently, CVOTs included subgroups of patients with multiple cardiovascular risk factors but without established cardiovascular disease [8–10]. Nonetheless, the overall cardiovascular risk of patients enrolled in most CVOTs was much higher than in the population of patients with T2D who could receive the new GLM in routine clinical practice. Other remarkable differences have been highlighted between CVOT populations and the typical outpatients with T2D, including age and sex distribution [11]. Indeed, small proportions of patients with T2D would satisfy enrolment criteria of CVOTs on GLP-1RA or SGLT2i and even smaller proportions actually have CVOT-like characteristics [12, 13]. For these reasons, there has been an intense debate on whether results of CVOTs can be transferred to the general real-world population of patients with T2D, irrespective of their cardiovascular risk profile [14, 15]. This is a clinically-relevant question informing on which and how many patients would benefit from GLM with CVOT-proven cardiovascular protective effect in routine care. Though prior studies have addressed the generalizability of trial populations, no study so far has explored whether CVOT findings, i.e. the drug’s effect on the outcome(s), can be transferred to a target population with different characteristics from that of the trial.

We herein used an innovative approach to transpose the effects of GLP-1RA or SGLT2i observed in the respective CVOTs to a large unselected target population of patients who were followed under routine specialist care and could potentially be prescribed such medications.

**Methods**

**Selection of CVOTs**

Since the method for transposing trial effects to the target population relies on the availability of stratum-specific information of effect [16], we selected CVOTs reporting the hazard ratio for the primary outcome in various subgroups of patients based on clinical characteristics of the trial population. CVOTs were identified based on literature search and then selected based on whether key information were available. The search string was: (“cardiovascular” AND “outcome” AND “randomized” AND “trial” AND “type 2 diabetes”). As the primary outcome of interest, we elected the 3-point major adverse cardiovascular events (3P-MACE), a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. Eventual co-primary outcome(s) were also considered [10]. For comparison, we also performed the same analysis on typical CVOTs that have shown neutral effects of the drugs under investigation with respect to the rate of cardiovascular events, such as those performed with dipeptidyl peptidase-4 inhibitors (DPP-4i).

**Target population**

In Italy, GLP-1RA and SGLT2i can be prescribed only by diabetes specialists. Therefore, as a target population of individuals with T2D who could receive such medications in real-life, we used the DARWIN-T2D (data from the real-world in type 2 diabetes) database [17]. DARWIN-T2D was a retrospective multicentre study collecting data from 46 diabetes specialist outpatient clinics in Italy. While DARWIN-T2D included longitudinal assessment of patients initiating a few selected glucose lowering medications [18], it also recorded cross-sectional data on all patients with T2D at their last available visit each participating Centre [19]. All patients aged 18 years or older and with a diagnosis of T2D were included, yielding a population of about 281,000 patients, evaluated between 2015 and 2016. Therefore, this was an unselected population of adults with T2D attending diabetes clinics, which is estimated to represent about 20% of the entire population of individuals with T2D attending diabetes clinics in Italy [20, 21]. Study design and methods for data collection, including definition of variables, have been described previously in detail [17]. Briefly, we collected data on demographics, anthropometrics, risk factors, laboratory values, complications, and medications at the last available visit up to December 31st, 2016. The study was conducted according to the principles of the Declaration of Helsinki and approved by ethics committees at all participating centres. Based on national regulations on retrospective studies with anonymous data, patients’ informed consent was waived.

**Transposition and statistical analysis**

The method for transposition is escribed as a flow-chart in Fig. 1. The most diffused setting in which transposition of trial effect is performed is when individual-level data for both the trial and the target population are available. In this case, patients in the trials are weighted by their probability to meet the inclusion criteria. Then, an outcome analysis is performed within the weighted trial data [22]. Contrariwise, in our study we disposed of individual-level data for the target population and aggregated data for CVOTs. As a consequence, we could not perform outcome analyses (i.e. weighting using simulated individual data or weighting using the method of moments, which require individual-level data for the trial), but we could use stratum-specific trial estimates to transpose the trial effect to the target population [23]. More in detail, we implemented a post-stratification approach based on aggregate data of CVOTs and individual data of the target population in DARWIN-T2D, with an inverse approach compared to that described previously [16, 23].
retained only patients from the target populations for whom all variables were available for each specific trial transposition. We excluded patients with missing data because no method has been validated to pool results of the transposition approach from multiple imputed datasets. For each CVOT transposition, we have used definitions of cardiovascular disease based on the real-world data closer to those of the CVOT, with some adjustments done as previously described [12]. Heart failure was defined using ICD-9 codes reported in the DARWIN-T2D database, which may differ from the definition used in CVOTs [24]. Continuous variables in DARWIN-T2D were categorized according to the CVOT stratum-specific estimates. Then, the subgroup-specific estimates of treatment effect in the CVOT and proportions of the categorized characteristics in DARWIN-T2D were used to calculate the treatment effect for the target population by weighting the average of the stratum-specific treatment effects according to proportions of a given characteristic in the target population.

As a simple example, let us consider the “gender” variable in the REWIND trial, where 46% of participants were women. In the target population, 44% of subjects were women. In REWIND, the stratum-specific HR estimates were 0.85 (95% C.I. 0.71–1.02) for females and 0.90 (95% C.I. 0.79–1.04) for males. Then, the weighted HR estimate for the variable “gender” is computed by the formula:

$$\text{Transposed HR}_j = \exp\left(\frac{\sum \ln(HR_i) * p_i}{\sum p_i}\right), i = 1.2$$

Fig. 1 A flow-chart of the transposition method. The figure illustrates the three-step procedure used to transpose a cardiovascular outcome trial (CVOT) result to the target population. An example from the REWIND study is described in the text.
where \( p_i \) states for proportion in DARWIN-T2D in the level \( i \) of the variable. In our example, the transposed HR was obtained as 
\[
\ln(0.85) + 0.44 + \ln(0.90) + 0.56 = -0.13,
\]
that exponentiated leads to a HR = 0.88 (Additional file 1: Table S1).

The standard deviations across strata were pooled to obtain the 95% confidence interval. The calculation was performed for one characteristic at a time. Then, the unweighted average of the estimated transposed treatment effect of each characteristic was used to summarize the post-stratification estimates of treatment effect. Analyses were performed using R version 3.5.2 [25].

**Results**

The analysis was conducted only for CVOTs having usable data for transposition. For example, transposition could not be performed for the CANVAS study because reporting of stratum-specific effects was not accompanied by numbers of patients in each stratum [26]. The analysis was not performed for HARMONY [27] because albipitide has never become clinically available. Only the primary endpoint was considered, because stratum-specific effects were most of the times not available for individual components of the 3P-MACE and other secondary outcomes. For the DECLARE study, transposition was performed for both co-primary outcomes [10].

The number of variables that defined stratum-specific effects ranged from a maximum of 28 for EMPA-REG [28] to a minimum of 6 for DECLARE [10]. Therefore, as shown in Table 1, different number and types of variables were used to perform transposition for different CVOT. This indicates that results of the transposition analysis cannot be compared across CVOTs.

After excluding patients with missing data of key variables, the target population of the DARWIN-T2D study was composed of a total of 139,726 patients, but not all information was available for all patients. Table 2 shows clinical characteristics of patients in the target population compared to those of patients enrolled in CVOTs (n = 95,816). The CVOT population was younger, with a shorter diabetes duration, was more obese, and had a two to threefold greater prevalence of cardiovascular disease, reflected by more frequent use of cardiovascular medications. Yet, median albumin excretion rate was lower than in the target population, likely because patients with advanced renal disease were excluded from CVOTs. Among glucose lowering medications, patients enrolled in CVOTs had more frequent use of sulphonylurea and insulin. On average, only 41.9% patients enrolled in the selected trials were recruited in Europe and 75.0% were white. The substantial difference between the CVOT and the target population was expected and forms the rationale for performing the transposition analysis.

After transposition to the target population, the estimated HR was significantly lower than 1.0 for LEADER [29], SUSTAIN-6 [30], REWIND [9] and DECLARE [10] (co-primary endpoint of cardiovascular death or hospitalization for heart failure). The HR for 3P-MACE in patients randomized to empagliflozin in EMPA-REG was 0.86 (95% C.I. 0.74–0.99) and changed to 0.88 (95% C.I. 0.74–1.03) when transposed to the target population. Figure 2 compares the HR (95% C.I.) of the effect observed in CVOT with the corresponding HR (95% C.I.) obtained after transposition to the target population. For each CVOT, subgroup-weighted mean of stratum-specific estimates from CVOTs are given in Additional file 1: Table S1–S10.

The effect on 3P-MACE observed in EXSCEL [31], PIONEER-6 [32] and DECLARE [10] was not significant in the trial and remained so after transposition. As expected, the transposed estimate of DPP-4i effects using stratum-specific data from TECOS [33] or SAVOR-TIMI [34] yielded neutral results also in the target population.

**Discussion**

Despite major differences between patients with T2D enrolled in CVOTs and patients with T2D seen in routine clinical practice [12–14], our transposition analysis shows that most significant results of CVOTs apply to the target real world population.

Due to the specific population of patients enrolled in CVOTs, doubts have been cast on whether significant protective effects observed for some of the active drugs being tested could be transferred to the entire population of patients who could receive such medications in clinical practice [12]. In most CVOTs, subgroup analyses performed for most, but not all, stratification variables showed no substantial heterogeneity in the effect, claiming for a direct clinical transferability of the findings. Nonetheless, several trends of interaction and a few nominally significant interactions between the assigned treatment and stratification variables may yield overall significant effects when transposed to a much different target population.

To the best of our knowledge, there is no prior attempt to transpose effects of diabetes medications observed in CVOTs to a real-world population, with quantitative estimates. Thus, our new findings can help reducing inertia in the use of GLM for which solid cardiorenal protective data exist [35].

The post-stratification method described by Hong et al. can be used to generalize trial results without accessing individual-level data [16]. The gold standard approach would require individual data from both CVOTs and the target population to predict probabilities of being sampled in the trial and to reweight
participants to reflect the target population of patient characteristics. However, accessing individual data of multiple CVOTs sponsored by different companies can be harnessed by compliance issues and conflicts of interest. Alternative methods, as the one we used, are subjected to biases and based on some critical assumptions. Specifically, this approach requires only categorical variables and is effective only when a small number of variables are taken into account [22]. In addition, it can be used only for one variable at a time, making the assumption of no correlation between them, which does not necessarily hold true. Further, results of transposition is strictly dependent on which and how many strata are available for the trial, such that the effects of important variables not considered for stratification are disregarded. Moreover, this approach is generally used when individual data are available for CVOT and aggregate data are available for the target population [16]. In our case, we applied the method with individual data for the target population and aggregate data for the CVOTs. Another limitation is the need to know the proportion of the target population in each strata [16].

| Table 1 Post-stratification variables |
|---------------------------------------|
|                                  | EMPA-REG | TECOS | SAVOR-TIMI | SUSTAIN-6 | LEADER | EXSCEL | REWIND | PIONEER-6 | DECLARE |
| Duration of diabetes              | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Age                               | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Sex                               | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| HbA1c                             | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| BMI                               | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Body weight                       | X        |        |            |            |         |         |         | X         |         |
| Systolic blood pressure           | X        | X      |            |            |         |         |         |           |         |
| Diastolic blood pressure          | X        |        |            |            |         |         |         |           |         |
| Established CVD                   | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Prior MI or Stroke                | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| PAD                               | X        |        |            |            |         |         |         |           |         |
| Previous MI                       | X        |        |            |            |         |         |         | X         |         |
| Heart failure                     | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| CVD risk factors                  | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Only cerebrovascular disease      | X        |        |            |            |         |         |         |           |         |
| eGFR                              | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Urinary albumin/creatinine ratio  | X        |        |            |            |         |         |         | X         |         |
| Anti-diabetic therapy             | X        |        |            |            |         |         |         | X         |         |
| Insulin                           | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Metformin                         | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Sulphonylurea                      | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Thiazolidinediones                | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| DPP-4i                            | X        |        |            |            |         |         |         | X         |         |
| Anti-hypertensive therapy         | X        | X      |            |            |         |         |         |           |         |
| RAS blockers                      | X        | X      |            |            |         |         |         |           |         |
| Calcium channel blockers          | X        | X      |            |            |         |         |         |           |         |
| Beta blockers                     | X        | X      |            |            |         |         |         |           |         |
| Diuretics                         | X        | X      |            |            |         |         |         |           |         |
| Aspirin                           | X        |        |            |            |         |         |         | X         |         |
| Statin                            | X        | X      |            |            |         |         |         |           |         |
| Europe                            | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Ethnicity                         | X        |        |            |            |         |         |         | X         |         |
| White                             | X        | X      | X          | X         | X       | X       | X       | X         | X       |
| Number of variables               | 28       | 20     | 18         | 14         | 13      | 12      | 9       | 9          | 6       |

For each cardiovascular outcome trial, we report which variables were used for post-stratification transposition to the target population.

BMI: body mass index, CVD: cardiovascular disease, PAD: peripheral arterial disease, MI: myocardial infarction, eGFR: estimated glomerular filtration rate, DPP-4: dipeptidyl peptidase-4, RAS: renin angiotensin system.
Table 2 Clinical characteristics

| Variable                     | Target population | CVOTs |
|------------------------------|-------------------|-------|
|                              | Number | Value | Number | Value |
| Duration of diabetes, years  | 139,700 | 12.1 (9.4) | 71,636 | 11.7 |
| Age, years                   | 139,708 | 68.8 (11.2) | 95,816 | 64.4 |
| Sex male, %                  | 139,726 | 57.1 | 95,816 | 66.4 |
| HbA1c, %                     | 132,717 | 7.3 (1.3) | 95,816 | 8.0 |
| mmol/mol                     | 56 (9) | 64 |
| BMI, kg/m²                   | 126,994 | 29.6 (5.5) | 95,816 | 31.6 |
| Body weight, kg              | 128,431 | 80.8 (17.1) | 39,332 | 89.1 |
| Systolic blood pressure, mm Hg | 104,305 | 137.2 (18.4) | 64,572 | 135.6 |
| Diastolic blood pressure, mm Hg | 104,226 | 77.5 (9.5) | 47,412 | 77.3 |
| Established CVD, %           | 139,726 | 28.9 | 95,816 | 67.5 |
| PAD, %                       | 139,726 | 6.0 | 53,603 | 14.4 |
| Previous MI, %               | 97,074 | 11.7 | 50,820 | 38.8 |
| Heart failure, %             | 139,726 | 1.4 | 92,633 | 13.5 |
| eGFR, ml/min/1.73 m²         | 113,593 | 75.7 (24.5) | 83,179 | 76.7 |
| Albumin creatinine ratio, mg/g (median) | 113,775 | 22.6 | 41,064 | 1.4 |
| Glucose-lowering therapy, %  | 139,726 | 93.3 | 95,816 | 95.0 |
| Insulin, %                   | 130,380 | 33.5 | 95,816 | 39.5 |
| Metformin, %                 | 130,380 | 71.3 | 95,816 | 77.3 |
| Sulphfonylurea, %            | 130,380 | 27.5 | 95,816 | 42.5 |
| Thiazolidinediones, %        | 130,380 | 5.0 | 78,656 | 4.1 |
| DPP-4 inhibitors, %          | 130,080 | 23.3 | 95,816 | 16.3 |
| SGLT-2 inhibitors, %         | 130,080 | 4.4 | 95,816 | 13.8 |
| GLP-1 receptor agonists, %   | 130,080 | 5.1 | 95,816 | 21.1 |
| Anti-hypertensive therapy, % | 117,632 | 80.1 | 37,592 | 92.3 |
| RAS blockers, %              | 117,632 | 67.0 | 92,633 | 79.2 |
| Calcium channel blockers, %  | 117,632 | 25.1 | 49,080 | 32.8 |
| Beta blockers, %             | 117,632 | 31.5 | 92,633 | 56.7 |
| Diuretics, %                 | 117,632 | 19.2 | 52,263 | 41.9 |
| Statin, %                    | 117,632 | 61.1 | 95,816 | 75.3 |
| Aspirin, %                   | 117,632 | 50.6 | 95,816 | 68.3 |

Data are presented as mean (SD) for continuous variables or as percentage for categorical variables. The number of patients with available information for each variable is shown for both populations.

and the proportion of missing data in DARWIN-T2D could lead to biased results.

It is important to note that most CVOTs reporting superiority of active drugs versus placebo for cardiovascular protection was confirmed after transposition to the real-world population. This is the case for LEADER, SUSTAIN-6, REWIND, and DECLARE (second co-primary endpoint), while it was not for EMPA-REG Outcome. The reasons why the significantly lower rate of 3P-MACE among patients randomized to empagliflozin in the EMPA-REG Outcome trial was not significant after transposition to the target population can be manifold. These include the presence of nominally significant heterogeneity observed in subgroups of patients divided by age and baseline HbA1c [28], the 2:1 ratio between patients on empagliflozin and those on placebo yielding small numbers of patients in some strata, and the large number of variables (n = 28) that composed strata used for transposition. With regards to the latter point, when we transposed EMPA-REG Outcome with the 6 strata used to transpose DECLARE, we obtained an estimated HR of 0.85 (95% C.I. 0.70–0.99) for the target population. To gather further insight into this point, we repeated the analysis to evaluate which stratifications made the HR transposed from EMPA-REG Outcome not significant, by backward elimination ordered by standard deviation of the estimate (from larger to smaller): the HR was still significant (0.85; 95% C.I. 0.71–0.99) with 11 of the initial 28 strata. However, this approach has not been validated. Therefore, to rule out that this finding was
Transposed that drug. We did not apply CVOT inclusion/exclusion criteria because we aimed to estimate the effect in an unselected target population. However, not all real-world patients with T2D are candidate for a therapy with GLP-1RA or SGLT2i, because of possible contraindications (e.g. advanced kidney disease) and eventual regulatory restrictions. With regards to the latter, we argue that, if significant benefits of GLP-1RA and SGLT2i on unselected patients with T2D hold true, regulatory limitations might be relieved in order to improve access to the best available care.

Conclusions
Notwithstanding the above-described limitations, we herein provide the first estimate that cardiovascular protection by diabetes drugs investigated in CVOTs could apply to a very different and highly heterogeneous population of patients with T2D seen in routine care.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-021-01300-y.

Acknowledgements
None.

Composition of the DARWIN-T2D Network:
Agostino Consoli and Gloria Formoso (Dipartimento di Medicina e Scienze dell’Invecchiamento—Università Degli studi G. D’Annunzio di Chieti-Pescara); Giovanni Grossi (Ospedale San Francesco di Paola—Azienda Sanitaria Provinciale di Cosenza); Achiropita Pucci (Azienda Sanitaria Provinciale di Cosenza); Giorgio Sesti and Francesco Andreozzi (Azienda Ospedaliero Universitaria di Catanzaro); Giuseppe Capobianco (Azienda Sanitaria Locale Napoli 2 Nord); Adriano Gatti (Ospedale San Gennaro dei Poveri—Azienda Sanitaria Locale Napoli 1 Centro); Riccardo Bonadonna, Ivana Zavaroni and Alessandra Del Cas (Azienda Ospedaliero Universitaria di Parma); Giuseppe Felace (Ospedale di Spilimbergo—Azienda per l’Assistenza Sanitaria n.5 Friuli Occidentale); Patrizia Li Voli (Ospedale di Pordenone—Azienda per l’Assistenza Sanitaria n.5 Friuli Occidentale); Raffaella Buzsett and Gaetano Leto (Ospedale Santa Maria Goretti—Azienda Sanitaria Locale di Latina); Gian Pio Sorice (Fondazione Polyclinico Universitario A. Gemelli, Roma); Paola D’Angelo (Ospedale Sandro Pertini—Azienda Sanitaria Locale Roma 2); Susanna Morano (Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma); Antonio Carlo Bossi (Ospedale di Treviglio—Azienda Socio Sanitaria Territoriale Bergamo Ovest);
Eduardo Duratòre (Ospedale Luini Confalonieri di Luino—Azienda Socio Sanitaria Territoriale Sette Laghi); Ivano Franzetti (Ospedale Sant’Antonio Abate di Gallarate—Azienda Socio Sanitaria Territoriale Valle Olona); Paola Silvia Morpurgo (Ospedale Fatebenefratelli—Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco); Emanuela Onzi (Fondazione IRCCS Cà Grandi—Ospedale Maggiore Policlinico di Milano); Fabrizio Querci (Ospedale Pesenti Fanorali di Alzano Lombardo—Azienda Socio Sanitaria Territoriale Bergamo Est); Massimo Boemt† and Federica D’Angelo (Presidio Ospedaliero di Ricerca INRCA-IRCCS di Ancona); Massimiliano Petrelli (Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona); Giuslana Aimaretti and Ioannis Karamouzis (Azienda Ospedaliero Universitaria Maggiore della Carità di Novara); Franco Cavolato (Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano); Giuseppe Saglietti† (Ospedale Madonna del Popolo di Omegna—Azienda Sanitaria Locale Verbano Cusio Ossola); Giuliana Gazzetta (Casa della Salute, Ugento—Distretto Socio Sanitario Gagliano del Capo—Azienda Sanitaria Locale di Lecce); Silvestre Cervone (Presidio ospedaliero San Marco in Lamis—Distretto Socio Sanitario San Marco in Lamis—Azienda Sanitaria Locale di Foggia); Eleonora Devangelio (Distretto Socio Sanitario di Massafra—Azienda Sanitaria Locale di Taranto); Olga Lamacchia (Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia); Salvatore Arena (Ospedale Umberto I—Azienda Sanitaria Provinciale di Siracusa); Antonino Di Benedetto (Azienda Ospedaliero Universitaria Policlinico G. Martino di Messina); Lucía Frittitra (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Palermo); Salvatore Piro (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Manfredi Rizzo, Roberto Chianetta and Carlo Mannina (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Roberto Anichini (Ospedale San Jacopo di Pistoia—Azienda USL Toscana Centro); Giuseppe Penno (Azienda Ospedaliero Universitaria Pisana); Anna Solini (Azienda Ospedaliero Universitaria Pisana); Bruno Fattor (Comprensorio Sanitario di Bolzano—Azienda Sanitaria della Provincia Autonoma di Bolzano); Enzo Bonora and Massimo Cigolini (Azienda Ospedaliero Universitaria Integra- grata di Verona); Annunziata Lamacchia and Nino Cristiano Chilelli (Complesso Socio Sanitario Ai Colli—Azienda ULSS n.6 Euganea); Maurizio Poli (Ospedale Girolamo Fracastoro di San Bonifacio—Azienda ULSS n.9 Scaligeri); Natalino Simioni and Vera Frison (Ospedale di Cittadella—Azienda ULSS n.6 Euganea); Carmela Vinci (Azienda ULSS n.4 Veneto Orientale).

Authors’ contributions
VS, study design, analysis, manuscript writing. PB, study design, manuscript revision. AA, study design and oversight, manuscript revision. GPF study design, analysis, manuscript writing. All authors read and approved the final manuscript.

Funding
Supported by the Italian Diabetes Society.

Data availability
Data used for this study are either publicly available or available from the corresponding author at a reasonable request.

Declarations
Ethics approval and consent to participate
The study protocol was approved by the ethical committee of the coordinating Center and approved by local ethics committees of all participating centers. Based on national regulations on retrospective studies with anonymous data, patients’ informed consent was waived.

Consent for publication
Not applicable for this manuscript.

Competing interests
AA received research grants, lecture or advisory board fees from: Merck Sharp & Dome, AstraZeneca, Novartis, Boehringer-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier, and Takeda. GPF received grants, honoraria or lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, Novo Nordisk, Sanofi, VS and PB have nothing to disclose.

Author details
1 Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. 2 Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. 3 Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.

Received: 3 March 2021 Accepted: 6 May 2021
Published online: 10 May 2021

References
1. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–93.
2. Schnell O, Standl E, Cos X, Heerspink HJ, Izhak B, Lalic N, Nauck M, Ceriello A. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.
3. Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15(1):111.
4. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, et al. Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: lessons learned and future directions. Circulation. 2020;141(10):843–62.
5. Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, Juni P, Farkouh ME, Udel RL. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020,8(5):418–35.
6. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JVF. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019,7(10):776–85.
7. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHW, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.
8. Schnell O, Standl E, Catinou I, Izhak B, Lalic N, Rahelic D, Skrha J, Valensi P, Ceriello A. Report from the 4th cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019,18(1):30.
9. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riemeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
10. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Probstfield J, Riesmeyer JS, Ceriello A. Report from the 4th cardiovascular outcome trial (CVOT) summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019,18(1):30.
11. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
12. Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
13. Probstfield J, Riesmeyer JS, Riddle MC, Udel RL, Jakel RT, Furtado RHW, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9.
14. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
15. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
16. Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
17. Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;393(10193):121–30.
14. Castellana M, Procino F, Sardone R, Trimillo P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):87.

15. Chatterjee S, Davies MJ, Khunti K. What have we learnt from “real world” data, observational studies and meta-analyses. Diabetes Obes Metab. 2018;20(Suppl 1):47–58.

16. Hong JL, Webster-Clark M, Jonsson Funk M, Sturmer T, Dempster SE, Cole SR, Herr I, LoCasale R. Comparison of methods to generalize randomized clinical trial results without individual-level data for the target population. Am J Epidemiol. 2019;188(2):426–37.

17. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A. Rationale and design of the DARWIN-T2D (DAPagliflozin Real World evidenNce in Type 2 Diabetes): a multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017;27(12):1089–97.

18. Fadini GP, Zatti G, Baldi I, Bottiglengo D, Consoli A, Giacconi A, Sesti G, Avogaro A. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes Metab. 2018;20(7):1781–6.

19. Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. J Endocrinol Invest. 2021. https://doi.org/10.1007/s40618-021-01501-y.

20. Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini GP, Martini N, Rossi E. Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. BMJ Open Diabetes Res Care. 2020;8(1):e001191.

21. Bonora E, Cataudella S, Marchesini G, Miccoli R, Vaccaro O, Fadini GP, Martini N, Rossi E. A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis. 2020;30(1):1945–53.

22. Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity scores to assess the generalizability of results from randomized trials. J R Stat Soc Ser A Stat Soc. 2001;174(2):369–86.

23. Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev Sci. 2015;16(3):475–85.

24. Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Satar N, McGuire DK, Januzzi JL, Stockbridge N, et al. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol. 2018;71(12):1379–90.

25. R core team: a language and environment for statistical computing. R Foundation for Statistical Computing. Wien, 2019.

26. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erduon N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

27. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN,Somerville MC, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

28. Zimman B, Wanner C, Lachin JM, Fitchett D, Bluemke H, Hantel S, Mathieu M, Devins T, Johansen OE, Woeber HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

29. Marso SP, Daniels GH, Brown-Forsten K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

30. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

31. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygyna Y, Buse JB, Chan JC, Choi J, Gustavsson SM, Iqbal N, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

32. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.

33. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Kom S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):322–42.

34. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.

35. Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Janez A, Kempler P, Komade I, Lalic NM, et al. Worldwide inertia to the use of cardio renal protective glucose-lowering drugs (SGLT2 and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.